FDA Review Finds Pfizer COVID-19 Vaccine Effective After First Dose

TUESDAY, Dec. 8, 2020 -- New data released Tuesday by the U.S. Food and Drug Administration Vaccines and Related Biological Products Advisory Committee suggest that Pfizer's two-dose COVID-19 vaccine works well protecting recipients against COVID-19.

The committee is scheduled to meet on Thursday to consider the Pfizer/BioNTech COVID-19 vaccine for emergency use authorization, CNBC reported.

According to the FDA, the data from Pfizer's COVID-19 vaccine trials were "consistent" with the agency's recommendations for an emergency use authorization. The data show that the vaccine provides protection after the first dose and that two doses are "highly effective" in preventing COVID-19.

"As such, FDA has determined that the Sponsor has provided adequate information to ensure the vaccine's quality and consistency for authorization of the product under an EUA," the agency said.

Today, the United Kingdom began inoculating its citizens with the Pfizer/BioNTech vaccine. The United States is expected to decide on the emergency approval of the vaccine before the end of the week, CNBC reported.

CNBC Article

FDA Briefing Document

© 2020 HealthDay. All rights reserved.

Posted: December 2020

Further Support and Information on COVID-19

Read this next

Pediatric Appendiceal Perforation Up During COVID-19 Pandemic

TUESDAY, Dec. 8, 2020 -- There was a statistically significant increased rate of appendiceal perforation in children presenting to the emergency department during the early weeks...

Masks Containing Metal Could Cause Burns During MRI, FDA Warns

TUESDAY, Dec. 8, 2020 -- Patients who wear face masks with metal parts or coatings during magnetic resonance imaging (MRI) could suffer facial burns, the U.S. Food and Drug...

Large U.S. Claims Study IDs Complications of COVID-19

TUESDAY, Dec. 8, 2020 -- Numerous complications of COVID-19 have been identified, according to a study published online Dec. 8 in CMAJ, the journal of the Canadian Medical...

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.